Recent evidence in the past 10 years now indicates that beyond its canonical role as a co-factor for NFkB signaling, the BCL3 protein modulates cancer progression and therapy resistance through distinct and novel mechanisms involving protein modifications and interactions with alternative oncogenic protagonists including c-Myc, WNT/β-catenin and STAT3. Here, MYC is linked to cancer.